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CONCLUSIONS: In a studied period, NICE published more positive recommenda-
tions for cancer drug technologies than AHTAPoL. The contradictory 
recommendations prevailed in the group of drug technologies appraised by both 
jurisdictions.
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OBJECTIVES: To develop targeted leaﬂ ets regarding cancer screening guidelines that 
take account the knowledge required by different target groups. METHODS: Before 
developing leaﬂ ets, public interest data regarding cancer screening were collected by 
the problem solving model (the so-called KJ method developed for ﬁ eld surveys in 
Japan). The KJ method includes two steps: label making of information corresponded 
to speciﬁ c issues and grouping similar concepts. Contents of leaﬂ ets were edited based 
on the results of the KJ methods but changed in the ﬁ nal version according to discus-
sions at a committee meeting involving public members. We compared the results of 
the KJ method and contents of the ﬁ nal version of the leaﬂ ets for the following groups: 
cervical cancer screening targeted at 20-year-old subjects (ﬁ rst group), cervical cancer 
screening targeted at subjects aged 30 years and older (second group), and 
colorectal cancer screening targeted at subjects aged 40 years and older (third 
group). RESULTS: Common interests among the three groups included targeting 
cancer and screening methods. Although the KJ method revealed that the ﬁ rst 
group expected broad information, in the ﬁ nal version of the leaﬂ et, only basic infor-
mation regarding participation in cancer screening programs remained. The ﬁ nal 
versions in group 2 and 3 almost corresponded to the ﬁ rst interest of an actual plan 
to participate in a screening program including details of the screening methods as 
well as physical and ﬁ nancial burden expected. Although information regarding the 
harm of cancer screening was initially included according to the results of the KJ 
methods in the second and third groups, there was no expectation in the ﬁ rst group. 
CONCLUSIONS: A targeted leaﬂ et is a powerful tool to share knowledge regarding 
cancer screening. We must understand the expectations of different target groups and 
prepare appropriate leaﬂ ets that support the decision to take part in cancer 
screening.
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OBJECTIVES: Recent evidence suggests that many breast cancer patients discontinue 
their hormonal therapy treatment regimen before the end of the recommended treat-
ment period, but reasons for treatment discontinuation are not well understood. 
Therefore, we examined reasons for hormonal therapy discontinuation in a European 
treatment cohort of female breast cancer (BC) patients. METHODS: Female patients 
ages 21+ with a diagnosis of BC between January 2006 and December 2008 were 
identiﬁ ed within IMS Oncology AnalyzerTM which provides retrospective, cross-sec-
tional, cancer-treatment data from 14 countries including France, Germany, Italy, 
Spain, and the United Kingdom and encompasses over 60,000 de-identiﬁ ed BC patient 
records from a physician panel of nearly 800 doctors in the EU5. Patients within the 
EU5 with early-stage BC (stages I-IIIa) who received hormonal therapy and for whom 
their physician provided a reason for discontinuing ﬁ rst course of therapy were 
included in the study. Patients enrolled in clinical trials were excluded. Reasons for 
discontinuation of therapy include course completion, progression of disease, stabiliza-
tion of disease, adverse events, terminal outlook, poor performance, and patient’s 
choice. RESULTS: 10,949 patients were identiﬁ ed. Approximately 57.2% discontin-
ued their ﬁ rst course of hormonal therapy prior to course completion. Of these 
patients, the top reasons for early discontinuation included progression of the disease 
(59.5%), adverse events (21.7%) and patient choice (10.1%). Mean duration of 
therapy for all patients was 95.4 months (range 45.5–152.1). Time to discontinuation 
was signiﬁ cantly shorter for those who quit due to Aes than those who quit by choice 
(36.2 months vs. 57.8 months, P < 0.0001). Of patients that discontinued due to AEs, 
hot ﬂ ushes (46.1%), pain (19.1%), and nausea and vomiting (14.0%) were the most 
commonly reported events. CONCLUSIONS: This analysis in a real world setting 
provides new insight into reasons for early discontinuation of hormonal therapy in 
the EU5.
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OBJECTIVES: The 21-gene Recurrence Score® (RS) is a validated assay for estimating 
a woman’s recurrence risk and chemotherapy beneﬁ t after the diagnosis of estrogen 
receptor positive (ER+), ESBC. We conducted a meta-analysis of RS’s inﬂ uence on 
treatment recommendations/decisions in lymph node negative (LN-) disease. 
METHODS: Literature was abstracted on cohort studies that reported the change in 
the recommendation or actual use of adjuvant chemotherapy (CT) for patients with 
ER+, LN-, ESBC before and after the RS. Outcomes evaluated were: treatment decision 
change from 1) CT plus hormone therapy (HT) to HT-only or 2) HT-only to CT plus 
HT. Actual treatment change was used when available. Reductions in the relative and 
absolute CT use associated with the RS were computed with Review Manager (5 
Version 5.0.24; Copenhagen: The Nordic Cochrane Centre, the Cochrane Collabora-
tion 2008). The relative change in CT was calculated as a before-to-after ratio of 
proportion of patients recommended or received CT, weighted by study sample size. 
RESULTS: Seven published studies (n = 912 patients) were eligible for the meta-
analysis. One was a prospective physician survey; six were retrospective chart reviews. 
a total of 569 (62%) patients were recommended CT prior to RS testing. After RS 
testing, 272 (30%) patients were recommended or received CT. In six of seven studies 
(n = 652 patients) that reported a treatment change, 212 (32%) patients switched from 
CT plus HT before RS to HT-only after RS. The absolute reduction in CT before and 
after RS testing was 30% (95% CI [−39%, −21%]). The relative reduction in CT 
before and after RS was 49% (95% CI [42%, 58%]). Estimates varied little when 
analysis omitted a single study. Limitations include heterogeneity in study designs. 
CONCLUSIONS: The meta-analysis shows consistent overall reduction in CT with 
the use of RS. 
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BACKGROUND: Retrospective claims databases are commonly used in outcomes 
research. Since physician charts are rarely available to conﬁ rm diagnoses, care must 
be taken when choosing patient populations. OBJECTIVES: To show how patient 
selection criteria affects sample size and chemotherapy treatment rates using an 
ovarian cancer (OC) population. METHODS: Patients were initially selected if 
they met the following inclusion criteria: at least one diagnosis of OC (ICD-9-CM 
codes 183.0x) between 1/1/2002 and 12/31/2007 (ﬁ rst OC diagnosis date termed 
index), 6 months pre-index and 12 months post-index eligibility, and no OC diagnosis 
in the 6 months pre-index. Additional criteria were imposed to further reﬁ ne the 
sample and assess variations in chemotherapy treatment rates. First, patients were 
required to have at least two diagnoses of OC at least 14 days apart. Next, patients 
were required to have both OC diagnoses on a record labeled as medical, surgical, 
facility, or pharmacy (i.e., ancillary records were excluded). RESULTS: A total of 
37,172 patients had at least one diagnosis of OC. Of those, 16,418 had 6 months 
pre-index and 12 months post-index eligibility with no pre-index OC diagnoses. In 
this population, 26% of patients received chemotherapy. When patients were also 
required to have one additional OC diagnosis at least 14 days from index, the sample 
size dropped to 7431 patients, of whom 47% received chemotherapy. When OC 
diagnoses on ancillary records were excluded, a total of 6213 patients were identiﬁ ed, 
of whom 52% received chemotherapy. CONCLUSIONS: Chemotherapy rates among 
OC patients varied signiﬁ cantly by the sample selection criteria used. Care must be 
taken to identify the correct patient sample in any retrospective database analysis since 
selection criteria affect the appropriateness of the sample, and thus the study 
results.
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OBJECTIVES: To provide an overview on published decision-analytic models evaluat-
ing various treatment strategies in chronic myeloid leukemia (CML). We sought to 
describe and analyze the structural and methodological approaches used and to derive 
recommendations for future CML models. METHODS: We performed a systematic 
literature review in electronic databases (Medline/PreMedline, EconLit, EMBASE, and 
others) to identify published studies evaluating CML treatment strategies using math-
ematical decision models. The models were required to compare different treatment 
strategies and to comprise relevant clinical health outcomes such as life-years gained 
or QALYs over a deﬁ ned time horizon and population. We used standardized forms 
for data extraction, description of study design, methodological framework, and data 
sources. RESULTS: We identiﬁ ed 14 different decision-analytic modeling studies, 
among which, 13 included economic evaluations. The modeling approaches varied 
substantially and comprised decision trees, Markov models, Monte Carlo simulations, 
and mathematical equations. Time horizons ranged from 2 years to lifetime. Health 
outcomes included survival, life expectancy, and QALYs. Compared treatment strate-
gies comprised bone or blood marrow transplantation, conventional chemotherapy, 
interferon-alpha, and ﬁ rst-generation tyrosine kinase inhibitor (TKI) imatinib. None 
of the models evaluated comprehensive personalized medicine strategies or second 
generation TKI (e.g., nilotinib, dasatinib). Only few models were validated using 
